Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · IEX Real-Time Price · USD
12.18
-0.29 (-2.33%)
Apr 30, 2024, 1:29 PM EDT - Market open
Nurix Therapeutics Revenue
Nurix Therapeutics had revenue of $80.89M in the twelve months ending February 29, 2024, with 94.02% growth year-over-year. Revenue in the quarter ending February 29, 2024 was $16.59M with 30.74% year-over-year growth. In the fiscal year ending November 30, 2023, Nurix Therapeutics had annual revenue of $76.99M with 99.31% growth.
Revenue (ttm)
$80.89M
Revenue Growth
+94.02%
P/S Ratio
8.95
Revenue / Employee
$284,813
Employees
284
Market Cap
717.45M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Nov 30, 2023 | 76.99M | 38.36M | 99.31% |
Nov 30, 2022 | 38.63M | 8.88M | 29.84% |
Nov 30, 2021 | 29.75M | 11.93M | 66.95% |
Nov 30, 2020 | 17.82M | -13.30M | -42.73% |
Nov 30, 2019 | 31.12M | - | - |
Nov 30, 2018 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Pediatrix Medical Group | 1.99B |
Canopy Growth | 248.53M |
Paragon 28 | 216.39M |
Evolus | 202.09M |
Silk Road Medical | 177.13M |
Aurinia Pharmaceuticals | 175.51M |
Atrion | 169.33M |
PureTech Health | 3.33M |
NRIX News
- 13 days ago - Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 18 days ago - Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering - GlobeNewsWire
- 18 days ago - Nurix Therapeutics Announces Proposed Public Offering - GlobeNewsWire
- 20 days ago - Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 20 days ago - Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies - GlobeNewsWire
- 21 days ago - Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6 - GlobeNewsWire
- 27 days ago - Nurix Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences - GlobeNewsWire